Receptor.AI and Sethera are partnering to develop a closed-loop drug discovery workflow that combines Sethera's polymacrocyclic peptide libraries with Receptor.AI’s physics-based modeling and AI capabilities. This collaboration aims to enhance the efficiency of lead optimization for hard-to-drug targets by iteratively refining experimental data through computational analysis, potentially reducing the number of design cycles needed to advance therapeutic candidates.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





